Tool for evaluating real world evidence in treatment of retinal disease

Tool for Evaluating RWE in the Treatment of Retinal Disease   Randomized clinical trials have long been held as the gold standard for evidence based medical practices. However, there is a growing consciousness about the value of incorporating data from real world based evidence into clinical decision making. Information from real world sources such

The Future of Glaucoma Therapy? Microneedles and the Reduction of Intraocular Pressure

The Future of Glaucoma Therapy? Microneedles and the Reduction of Intraocular Pressure Around 75 million people suffer from glaucoma, making it the world’s leading eye disorder that causes irreversible blindness. Vision loss in glaucoma patients is often accompanied by the dysfunction of the retinal ganglion cell axons. This is believed to

Sexual Dysfunction in Prostate Cancer Treatments: Study Results

Study Results: The Effects of Sexual Dysfunction in Prostate Cancer Patients Prostate cancer is the most common cancer in males, with more than 57,000 new cases each year. It accounts for around 26% of all male cancer cases. About one in six individuals with prostate cancer has advanced disease progression. Treatment of

Diagnosis And Management of Nocardia Keratitis

Diagnosis And Management of Nocardia Keratitis Keratitis refers to infection of the cornea, the dome covering the eye’s iris and pupil. Keratitis may or may not be caused by an infection. Minor injury to the eye, extended-wear contact lenses, or foreign bodies are the most common causatives of non-infectious keratitis. Infectious

Retinal Nerve Fiber Layer Thickness In Alzheimer’s Disease

Retinal Nerve Fiber Layer Thickness In Alzheimer’s Disease Worldwide, nearly 50 million people live with Alzheimer’s or related dementia according to Alzheimer's Disease International (ADI). If breakthroughs are not discovered, this population could triple to 152 million by the year 2050. Alzheimer’s disease (AD) accounts for around two-thirds of all dementia

Case Study- Can Giant Cell Arteritis and Myeloproliferative Neoplasm Cause Sudden Onset Vision Loss?

Case Study- Can Giant Cell Arteritis and Myeloproliferative Neoplasm Cause Sudden Onset Vision Loss? Patient: A 75-year-old man with a history of sudden (painless) loss of vision in the right eye along with recent jaw claudication and weight loss. Case Report: According to his accounts, his vision loss developed five days before his consultation.

Analysis of The Study on Adverse Reactions to 1% Cyclopentolate Eye Drop in Children

Analysis of The Study on Adverse Reactions to 1% Cyclopentolate Eye Drop in Children Cyclopentolate hydrochloride is a drug used before routine eye examinations such as refraction exams. It is often characterized by a faster onset and shorter duration of action compared to its alternative cycloplegic eye drop atropine sulfate hydrate. Refractive

Use of nanotechnology to deliver topical ophthalmic medications

nanotechnology medicine

Use of nanotechnology to deliver topical ophthalmic medications Topical drug delivery systems are widely used in transdermal, mucous membrane, ophthalmic, and otic applications as they are highly versatile, effective, and convenient. However, medication delivery complications such as drug solubility, bioavailability, timed release, and inaccurate physical targeting do exist. Recent advancements in nanotechnology